,

Prescient Therapeutics: Next Gen CAR-T Platform a Potential Game Changer – Independent Investment Research

July 3, 2020

PTX has acquired the exclusive global licence to a universal immune receptor (UIR) platform from the University of Pennsylvania (Upenn) and a non-exclusive licence to use the Spytag/SpyCatcher molecular binding system used by the UIR platform.

The company intends to use these licences and technology to build OmniCAR, a next generation cell therapy platform. OmniCAR has the potential to be a game changer for the company with UIRs having the potential to address a number of issues with the current (first generation) CAR-T cell therapies, allowing for more safe and effective treatment of blood cancers and boosting the potential use of CAR-T cell therapy in solid tumours, something that has proved elusive to date. The platform is currently in the preclinical stage of development with PTX seeking to undertake a combination of internal and external development.

Click here to read the full report (report/PDF Download)

Related Post

This investor centre was built by Reach Markets

©2022 Reach Markets

×

Do you qualify as a Wholesale (708) investor?

Wholesale 708 Sophisticated Investors are individuals or entities who generally qualify under Sections 708(8) and s761G(7) of the Corporations Act based on the gross income and/or net assets test verified by a qualified accountant.
  • A gross income of $250,000 or more per annum in each of the previous two financial years; or
  • Net assets of at least $2.5 million; and
  • A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
×

Any advice is general only

Any advice provided by Reach Markets, the Lead Manager on this offer, including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice.

×

Receive email updates

What is a 708 investor?

By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.